Traci Umberger Sells 10,500 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Traci Umberger sold 10,500 shares of the business’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $26.69, for a total transaction of $280,245.00. Following the completion of the transaction, the insider owned 136,633 shares in the company, valued at approximately $3,646,734.77. The trade was a 7.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Kestra Medical Technologies Stock Performance

Kestra Medical Technologies stock traded down $0.45 during trading on Wednesday, hitting $26.52. The stock had a trading volume of 489,936 shares, compared to its average volume of 289,819. The stock’s 50 day moving average is $26.29 and its two-hundred day moving average is $21.37. Kestra Medical Technologies, Ltd. has a 1 year low of $13.25 and a 1 year high of $30.00. The stock has a market cap of $1.55 billion and a price-to-earnings ratio of -8.37. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.26.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Quarry LP purchased a new stake in shares of Kestra Medical Technologies in the 1st quarter worth about $33,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Kestra Medical Technologies during the third quarter valued at $48,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Kestra Medical Technologies during the second quarter valued at approximately $54,000. BNP Paribas Financial Markets raised its stake in shares of Kestra Medical Technologies by 148.9% in the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares during the last quarter. Finally, Brown Brothers Harriman & Co. boosted its holdings in shares of Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after acquiring an additional 656 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Stifel Nicolaus set a $30.00 target price on shares of Kestra Medical Technologies in a research report on Friday, December 12th. Wells Fargo & Company boosted their target price on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Wall Street Zen downgraded Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Sunday, September 28th. The Goldman Sachs Group lifted their price target on Kestra Medical Technologies from $22.00 to $25.00 and gave the company a “neutral” rating in a research report on Saturday, December 13th. Finally, BTIG Research started coverage on Kestra Medical Technologies in a research note on Tuesday, November 18th. They issued a “buy” rating and a $32.00 target price for the company. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Kestra Medical Technologies presently has an average rating of “Moderate Buy” and an average price target of $29.14.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.